![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The recently-agreed merger between Upjohn and Pharmacia will create a company with annual pharmaceutical sales in the region of $7bn, placing the new company in the top five in terms of pharmaceutical sales. Currently, Upjohn has a total of fifty in-house and nineteen licensed-in products under development. Neurologicals (dopamine/5-HT ligands) and antibacterials (oxazolidinones) dominate the company's research, but both cardiovascular and musculoskeletal also feature significantly. However, the newly merged company, with its combined R&D pipeline, is expected to have a strong portfolio of anticancer compounds. This article analyses the patenting activity of Upjohn, prior to the merger, and, along with part one of this profile, indicates the likely strengths of the new company.